Particle.news
Download on the App Store
5 ARTICLES
·
yesterday

FDA and CDC Pause Chikungunya Vaccine for Older Adults Over Safety Concerns

U.S. health agencies recommend halting use of Valneva’s IXCHIQ vaccine in individuals aged 65 and older after reports of serious adverse events, while investigations continue.

Image
FILE - A patient infected with chikungunya looks out from mosquito netting at the Clinicas Hospital in San Lorenzo, Paraguay, Friday, March 3, 2023. (AP Photo/Jorge Saenz, file)
Image
Image

Overview

  • The FDA and CDC have jointly recommended pausing the administration of Valneva’s IXCHIQ chikungunya vaccine for adults aged 65 and older due to reports of serious adverse events.
  • The precaution follows six U.S. cases of heart or brain symptoms in older individuals with underlying conditions, reported shortly after vaccination, including one fatality.
  • No causal link between the vaccine and adverse events has been confirmed, and investigations by U.S. and European regulators are ongoing.
  • The vaccine remains authorized for individuals aged 18 to 60 in the U.S. and 12 to 64 in Europe, with over 40,000 doses administered globally.
  • The U.S. government has advised travelers aged 60 and older to avoid the vaccine while safety reviews are conducted, and a second chikungunya vaccine is under consideration for broader use.